ADIAL PHARMACEUTICALS, INC. current report, 12 December 2019

Full document

Business Context and Reporting Period

Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 12, 2019
Reporting Period: Specific event date (December 12, 2019)
Business Context: The Company is an emerging growth company developing AD04, an investigational new drug for the treatment of alcohol use disorder. This filing reports the entry into a material definitive agreement regarding the administration of a behavioral therapy program for an upcoming Phase 3 clinical trial.

Key Financial Metrics

This filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or general debt/liquidity metrics. Specific financial data related to the reported transaction includes:

  • Amounts Paid to Date: $39,064 paid to Psychological Education Publishing Company (PEPCO) under the Statement of Work (SOW).
  • Original Estimated Balance: $274,779.
  • Revised Total Price: $219,823 fixed price for all remaining services required for the Brief Behavioral Compliance Enhancement Treatment (BBCET).
  • Discount: 20% discount applied to remaining services.

Material Changes and Agreements

On December 12, 2019, the Company entered into an Amendment to the SOW attached to the Master Services Agreement (MSA) dated July 5, 2019, with PEPCO. Key changes include:

  • Service Provider Relationship: PEPCO is owned by an affiliate of the Company, Dr. Bankole Johnson (Chief Medical Officer and largest stockholder).
  • Cost Reduction: The Amendment fixes the total price for remaining services at $219,823, reflecting a 20% discount on the previously estimated balance.
  • Security and Guaranty: Dr. Johnson executed a guaranty of PEPCO's performance, secured by a pledge of 600,000 shares of the Company's common stock beneficially owned by him.
  • Lock-Up Agreement: Dr. Johnson agreed not to transfer or dispose of his currently owned shares until after January 1, 2021.

Guidance, Outlook, and Risks

Outlook: The agreement supports the Company's upcoming Phase 3 clinical trial for AD04 using the BBCET behavioral therapy program.
Risks and Contingencies:

  • Related Party Transaction: The service provider is owned by the Company's CMO and largest stockholder, creating a related party transaction risk.
  • Performance Risk: While a guaranty and stock pledge are in place, the Company relies on PEPCO's performance for the clinical trial support.
  • Liquidity of Shares: The lock-up agreement restricts the liquidity of 600,000 shares held by Dr. Johnson until 2021.
Management Commentary: The filing focuses on the terms of the amendment and security agreements rather than broader strategic commentary.

Investor Verification Checklist

  • Verify the terms of the Amendment to the SOW (Exhibit 10.1) to confirm the scope of services and the fixed price of $219,823.
  • Review the Guaranty (Exhibit 10.2) and Pledge and Security Agreement (Exhibit 10.3) to understand the recourse available if PEPCO fails to perform.
  • Confirm the status of the 600,000 pledged shares and the enforceability of the Lock-Up Agreement (Exhibit 10.4) through January 1, 2021.
  • Assess the potential impact of the related party transaction on the Company's cash flow and the integrity of the Phase 3 trial data.